我们曾研究过聚轮烷（PR）衍生物与葡聚糖-寡胺类基因转染系统，在提高转染率与降低PEI 毒性方面取得了一定成效，但始终未能解决抗癌药物多药耐药问题与基因治疗显效问题，为此，本课题在自己与前人研究超分子的组装药物载体的基础上，设计了一种具有某些肿瘤靶向功能并同时传递基因与药物的超分子自组装载体MPC。该载体由MC11 功能肽改性的低分子量PEI 交联的β-环糊精组成，对含有成纤生长因子受体FGFR 的多种肿瘤具有靶向作用，同时能携带p53 基因与紫杉醇(PTX)药物，形成纳米给药复合体系。我们已初步组装了该体系并进行了表征。理论与初步试验表明，该体系不仅能增强p53 基因的表达水平，而且还能降低PTX 多药耐药性（MDR）与系统的副作用，具有明显的协同效应。该体系未见报道，创新性强，具有学术研究价值与潜在应用前景。

This work is to develop a new carrier for cancer therapy with combination of drug treatment and gene therapy. We have designed a supramolecular co-delivery system that can efficiently delivery therapeutic p53 gene and paclitaxel(PTX) into cancer cell lines that express fibroblast growth factor receptor(FGFR) to achieve synergistic therapeutic effect. This system was synthesized by coupling MC11 peptide with cross-linked PEI-β-cyclodextrins. The PTX can be loaded within the hydrophobic cavities of β-CD. The cationic PEI arms surrounding the β-CD are able to further condense p53 gene into drug-loaded polyplexes. The co-delivery system is expected to exert a combined therapeutic effect，minimize multiple drug resistance(MDR) and system side effects.